The newest CETP inhibitor, obicetrapib, is currently under active investigation in multiple clinical trials and shows significant promise as a means to favorably modify lipids and theoretically reduce risk of atherosclerotic cardiovascular disease (ASCVD). Here, CETP is linked to atherosclerosis.